JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Janux Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.74+0.23 (+1.39%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-1576.7%
Net margin
-1136.3%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -5.6% | +5.1% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 60.1% | -11.5% | |
| Return on assets | – | – | -11.0% | |
| Current ratio | – | 5.05 | 39.04 | |
| Capex to revenue | – | – | 10.4% | |
| Diluted shares | – | 1M | 62M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Janux Therapeutics generated $236.52M from operations and spent $11.18M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$236.52M
Used
$11.18M
Capital expenditure$11.18M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1136.3%
×Asset turnover0.01×
×Equity multiplier1.04×
=Return on equity, FY2025-11.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1136.3% | 0.01× | 1.04× | -11.5% |
| FY2024 | -651.6% | 0.01× | 1.05× | -10.1% |
| FY2023 | -721.2% | 0.02× | 1.12× | -17.5% |
| FY2022 | -732.2% | 0.02× | 1.08× | -18.4% |
| FY2021 | -898.3% | 0.02× | 1.13× | -18.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$113.63M
- Cash generatingOperating cash flow above zero-$82.24M
- Return on assets improvedROA up on the prior year-18.1% → -10.7%
- Earnings backed by cashOperating cash flow above net income-$82.24M vs -$113.63M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose59.21 → 39.04
- No dilutionShare count did not rise54M → 62M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.03 → 0.01